Table 4.
Multivariate analysis of prognostic factors in patients with venous thromboembolism (N = 51)
| Overall survival (OS) | |||
|---|---|---|---|
| Hazard ratio | 95% CI | P-value | |
| Time of VTE occurrence (early vs. late) | 3.768 | 1.705–8.328 | 0.001 |
| Khorana score (high-risk vs. intermediate-risk) | 1.005 | 0.454–2.224 | 0.990 |
| Number of metastatic organs (≥3 vs. < 3) | 5.961 | 1.640–21.665 | 0.007 |
| Hb (< 10 g/dL vs. ≥10 g/dL) | 1.277 | 0.344–4.739 | 0.714 |
| Na (< 135 mmol/L vs. ≥135 mmol/L) | 0.913 | 0.334–2.496 | 0.859 |
| Albumin (< 3.5 g/dL vs. ≥3.5 g/dL) | 1.605 | 0.482–5.343 | 0.441 |
| CA 19–9 (≥1000 U/mL vs. < 1000 U/mL) | 1.74 | 0.920–3.289 | 0.088 |
| Lung metastases (Yes vs. No) | 1.822 | 0.909–3.651 | 0.091 |
NLR neutrophil-to-lymphocyte ratio, Hb hemoglobin, CA19–9 cancer antigen 19–9; LN lymph node